NCT05626634: Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy |
|
|
| Active, not recruiting | 2 | 50 | US, RoW | LP352, bexicaserin | Longboard Pharmaceuticals | Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome | 10/24 | 10/24 | | |
PACIFIC, NCT05364021: Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies |
|
|
| Completed | 1/2 | 52 | US, RoW | LP352, Placebo, Placebo Comparator | Longboard Pharmaceuticals | Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome | 11/23 | 11/23 | | |
